Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bilastine - FAES Farma

Drug Profile

Bilastine - FAES Farma

Alternative Names: Aligrin; Bellozal; Bilador; Bilahist; Bilanoa; Bilaska; Bilaxten; Bilaz; Bilidren; BLEXTEN; Borenar; Clatra; Drynol; F-96221-BM; Fortecal; Gosall; Ibis; Ilaxten; Inorial; Labixten; Lamiastine; Lendin; Lergonix; Nasitop; Nixar; Obalix; Olisir; Omarit; Opexa; Revitelle; Robilas; TAC-202; Vitador; Xados; Zilas

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FAES Farma
  • Developer Aralez Pharmaceuticals Inc.; FAES Farma; Menarini; Menarini Asia-Pacific; Miravo Healthcare; Taiho Pharmaceutical; Yuhan
  • Class Antiallergics; Antihistamines; Benzimidazoles; Eye disorder therapies; Piperidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Chronic urticaria; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis
  • Phase III Allergic rhinoconjunctivitis
  • No development reported Unspecified
  • Discontinued Angioedema

Most Recent Events

  • 30 Nov 2022 FAES Farma completes a phase-III trial in Allergic conjunctivitis (In children, In adolescents) in Spain (Ophthalmic) (NCT04810390)
  • 01 Mar 2022 Launched for Chronic-urticaria (In adolescents, In children) in Canada (PO)
  • 01 Mar 2022 Launched for Seasonal allergic rhinitis (In adolescents, In children) in Canada (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top